Multi-scale modeling of HIV-1 proteins

Journal of Molecular Structure: THEOCHEM

Volumn 898, Issue 1-3, 2009, Pages 97-105

  Carnevale, Vincenzo ^a   Raugei, Simone ^b   Neri, Marilisa ^c   Pantano, Sergio ^d   Micheletti, Cristian ^b   Carloni, Paolo ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SISSA   (Italy)

^c EPFL   (Switzerland)

^d INSTITUT PASTEUR DE MONTEVIDEO   (Uruguay)

Author keywords

Bioinformatics; Coarse grained; DFT; MD simulations; QM MM

Indexed keywords

EID: 60749129164     PISSN: 01661280     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.theochem.2008.11.028     Document Type: Article

References (72)

1. Calmy A., Pascual F., and Ford N. HIV drug resistance. N. Engl. J. Med. 350 (2004) 2720-2721
2. Clavel F., and Hance A.J. HIV drug resistance. N. Engl. J. Med. 350 (2004) 1023-1035
3. Martinez-Cajas J.L., and Wainberg M.A. Antiretroviral therapy: optimal sequencing of therapy to avoid resistance. Drugs 68 (2008) 43-72
4. Sterjovski J., Churchill M.J., Wesselingh S.L., and Gorry P.R. HIV-1 entry inhibitors: classes, applications and factors affecting potency. Curr. HIV Res. 4 (2006) 387-400
5. Van M.B., Busschots K., Vandekerckhove L., Christ F., and Debyser Z. Cellular co-factors of HIV-1 integration. Trends Biochem. Sci. 31 (2006) 98-105
6. Athanassiou Z., Patora K., Dias R.L., Moehle K., Robinson J.A., and Varani G. Structure-guided peptidomimetic design leads to nanomolar beta-hairpin inhibitors of the Tat-TAR interaction of bovine immunodeficiency virus. Biochemistry 46 (2007) 741-751
7. Kohl N.E., Emini E.A., Schleif W.A., Davis L.J., Heimbach J.C., Dixon R.A., Scolnick E.M., and Sigal I.S. Active human immunodeficiency virus protease is required for viral infectivity. Proc. Natl. Acad. Sci. USA 85 (1988) 4686-4690
8. Seelmeier S., Schmidt H., Turk V., and von der H.K. Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. Proc. Natl. Acad. Sci. USA 85 (1988) 6612-6616
9. Baca M., and Kent S.B. Catalytic contribution of flap-substrate hydrogen bonds in "HIV-1 protease" explored by chemical synthesis. Proc. Natl. Acad. Sci. USA 90 (1993) 11638-11642
10. Fitzgerald P.M., and Springer J.P. Structure and function of retroviral proteases. Annu. Rev. Biophys. Biophys. Chem. 20 (1991) 299-320
11. Hong L., Zhang X.C., Hartsuck J.A., and Tang J. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance. Protein Sci. 9 (2000) 1898-1904
12. Suguna K., Padlan E.A., Smith C.W., Carlson W.D., and Davies D.R. Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. Proc. Natl. Acad. Sci. USA 84 (1987) 7009-7013
13. Collins J.R., Burt S.K., and Erickson J.W. Flap opening in HIV-1 protease simulated by 'activated' molecular dynamics. Nat. Struct. Biol. 2 (1995) 334-338
14. Freedberg D.I., Wang Y.X., Stahl S.J., Kaufman S.J., Wingfield P.T., Kiso Y., and Torchia D.A. Flexibility and Function in HIV Protease: Dynamics of the HIV-1 Protease Bound to the Asymmetric Inhibitor Kynostatin 272 (KNI-272). J. Am. Chem. Soc. 120 (1998) 7916-7923
15. Katoh E., Yamazaki T., Kiso Y., Wingfield P.T., Stahl S.J., Kaufman J.D., and orchia D.A. Determination of the rate of monomer interchange in a ligand-bound homodimeric protein from NOESY cross peaks: application to the HIV Protease/KNI-529 complex. J. Am. Chem. Soc. 121 (2008) 2607-2608
16. Perryman A.L., Lin J.H., and McCammon J.A. HIV-1 protease molecular dynamics of a wild-type and of the V82F/I84V mutant: possible contributions to drug resistance and a potential new target site for drugs. Protein Sci. 13 (2004) 1108-1123
17. Schock H.B., Garsky V.M., and Kuo L.C. Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity. J. Biol. Chem. 271 (1996) 31957-31963
18. Mahalingam B., Louis J.M., Hung J., Harrison R.W., and Weber I.T. Structural implications of drug-resistant mutants of HIV-1 protease: high-resolution crystal structures of the mutant protease/substrate analogue complexes. Proteins 43 (2001) 455-464
19. Piana S., and Carloni P. Conformational flexibility of the catalytic Asp dyad in HIV-1 protease: an ab initio study on the free enzyme. Proteins 39 (2000) 26-36
20. Piana S., Carloni P., and Parrinello M. Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease. J. Mol. Biol. 319 (2002) 567-583
21. Piana S., Bucher D., Carloni P., and Rothlisberger U. Reaction mechanism of HIV-1 protease by hybrid car-parrinello/classical md simulations. J. Phys. Chem. B 108 (2004) 11139-11149
22. Bjelic S., and Aqvist J. Catalysis and linear free energy relationships in aspartic proteases. Biochemistry 45 (2006) 7709-7723
23. Szeltner Z., and Polgar L. Rate-determining steps in HIV-1 protease catalysis. The hydrolysis of the most specific substrate. J Biol. Chem. 271 (1996) 32180-32184
24. Hyland L.J., Tomaszek Jr. T.A., and Meek T.D. Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism. Biochemistry 30 (1991) 8454-8463
25. Miller M., Schneider J., Sathyanarayana B.K., Toth M.V., Marshall G.R., Clawson L., Selk L., Kent S.B., and Wlodawer A. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science 246 (1989) 1149-1152
26. Cornell W.D., Cieplak P., Bayly C.I., Gould I.R., Merz K.M., Ferguson D.M., Spellmeyer D.C., Fox T., Caldwell J.W., and Kollman P.A. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J. Am. Chem. Soc. 117 (1995) 5179-5197
27. Micheletti C., Carloni P., and Maritan A. Accurate and efficient description of protein vibrational dynamics: comparing molecular dynamics and Gaussian models. Proteins 55 (2004) 635-645
28. Piana S., Carloni P., and Rothlisberger U. Drug resistance in HIV-1 protease: flexibility-assisted mechanism of compensatory mutations. Protein Sci. 11 (2002) 2393-2402
29. Neri M., Anselmi C., Cascella M., Maritan A., and Carloni P. Coarse-grained model of proteins incorporating atomistic detail of the active site. Phys. Rev. Lett. 95 (2005) 218102
30. Neri M., Baaden M., Carnevale V., Anselmi C., Maritan A., and Carloni P. Microseconds dynamics simulations of the outer-membrane protease T. Biophys. J. 94 (2008) 71-78
31. Carnevale V., Raugei S., Piana P., and Carloni P. On the nature of the reaction intermediate in the HIV-1 protease: a quantum chemical study. Comput. Phys. Commun. 179 (2008) 120-123
32. Rao J.K., Erickson J.W., and Wlodawer A. Structural and evolutionary relationships between retroviral and eucaryotic aspartic proteinases. Biochemistry 30 (1991) 4663-4671
33. Blundell T.L., Cooper J.B., Sali A., and Zhu Z.Y. Comparisons of the sequences, 3-D structures and mechanisms of pepsin-like and retroviral aspartic proteinases. Adv. Exp. Med. Biol. 306 (1991) 443-453
34. Cascella M., Micheletti C., Rothlisberger U., and Carloni P. Evolutionarily conserved functional mechanics across pepsin-like and retroviral aspartic proteases. J. Am. Chem. Soc. 127 (2005) 3734-3742
35. Tang J., James M.N., Hsu I.N., Jenkins J.A., and Blundell T.L. Structural evidence for gene duplication in the evolution of the acid proteases. Nature 271 (1978) 618-621
36. Carnevale V., Pontiggia F., and Micheletti C. Structural and dynamical alignment of enzymes with partial structural similarity. J. Phys.: Condens. Mat. 19 (2007) 285206
37. Carnevale V., Raugei S., Micheletti C., and Carloni P. Convergent dynamics in the protease enzymatic superfamily. J. Am. Chem. Soc. 128 (2006) 9766-9772
38. Zen A., Carnevale V., Lesk A.M., and Micheletti C. Correspondences between low-energy modes in enzymes: dynamics-based alignment of enzymatic functional families. Protein Sci. 17 (2008) 918-929
39. Blundell T.L., and Srinivasan N. Symmetry, stability, and dynamics of multidomain and multicomponent protein systems. Proc. Natl. Acad. Sci. USA 93 (1996) 14243-14248
40. Carnevale V., Raugei S., Micheletti C., and Carloni P. Large-scale motions and electrostatic properties of furin and HIV-1 protease. J. Phys. Chem. A 111 (2007) 12327-12332
41. Hong L., Koelsch G., Lin X., Wu S., Terzyan S., Ghosh A.K., Zhang X.C., and Tang J. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290 (2000) 150-153
42. Piana S., Sebastiani D., Carloni P., and Parrinello M. Ab initio molecular dynamics-based assignment of the protonation state of pepstatin A/HIV-1 protease cleavage site. J. Am. Chem. Soc. 123 (2001) 8730-8737
43. Smith R., Brereton I.M., Chai R.Y., and Kent S.B. Ionization states of the catalytic residues in HIV-1 protease. Nat. Struct. Biol. 3 (1996) 946-950
44. Northrop D.B. Follow the protons: a low-barrier hydrogen bond unifies the mechanisms of the aspartic proteases. Acc. Chem. Res. 34 (2001) 790-797
45. Cho Y.K., Rebholz K.L., and Northrop D.B. Solvent isotope effects on the onset of inhibition of porcine pepsin by pepstatin. Biochemistry 33 (1994) 9637-9642
46. Vidossich P., Piana S., Miani A., and Carloni P. Deuterium isotope effects in A:T and A:U base pairs: a computational NMR study. J. Am. Chem. Soc. 128 (2006) 7215-7221
47. Carroll R., Martarano L., and Derse D. Identification of lentivirus tat functional domains through generation of equine infectious anemia virus/human immunodeficiency virus type 1 tat gene chimeras. J. Virol. 65 (1991) 3460-3467
48. Derse D., Carvalho M., Carroll R., and Peterlin B.M. A minimal lentivirus Tat. J. Virol. 65 (1991) 7012-7015
49. Dorn P., DaSilva L., Martarano L., and Derse D. Equine infectious anemia virus tat: insights into the structure, function, and evolution of lentivirus trans-activator proteins. J. Virol. 64 (1990) 1616-1624
50. Friedler A., Friedler D., Luedtke N.W., Tor Y., Loyter A., and Gilon C. Development of a functional backbone cyclic mimetic of the HIV-1 Tat arginine-rich motif. J. Biol. Chem. 275 (2000) 23783-23789
51. Montembault M., Vo-Thanh G., Deyine A., Fargeas V., Villieras M., Adjou A., Dubreuil D., Esquieu D., Gregoire C., Opi S., Peloponese J.M., Campbell G., Watkins J., de M.J., Aubertin A.M., Bailly C., Loret E., and Lebreton J. A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor. Bioorg. Med. Chem. Lett. 14 (2004) 1543-1546
52. Kiernan R.E., Vanhulle C., Schiltz L., Adam E., Xiao H., Maudoux F., Calomme C., Burny A., Nakatani Y., Jeang K.T., Benkirane M., and Van Lint C. HIV-1 tat transcriptional activity is regulated by acetylation. EMBO J. 18 (1999) 6106-6118
53. Marzio G., Tyagi M., Gutierrez M.I., and Giacca M. HIV-1 tat transactivator recruits p300 and CREB-binding protein histone acetyltransferases to the viral promoter. Proc. Natl. Acad. Sci. USA 95 (1998) 13519-13524
54. Pantano S., and Carloni P. Comparative analysis of HIV-1 Tat variants. Proteins 58 (2005) 638-643
55. Pantano S., Tyagi M., Giacca M., and Carloni P. Amino acid modification in the HIV-1 Tat basic domain: insights from molecular dynamics and in vivo functional studies. J. Mol. Biol. 318 (2002) 1331-1339
56. Chaloin O., Peter J.C., Briand J.P., Masquida B., Desgranges C., Muller S., and Hoebeke J. The N-terminus of HIV-1 Tat protein is essential for Tat-TAR RNA interaction. Cell Mol. Life Sci. 62 (2005) 355-361
57. Mujtaba S., He Y., Zeng L., Farooq A., Carlson J.E., Ott M., Verdin E., and Zhou M.M. Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol. Cell 9 (2002) 575-586
58. Pantano S., Marcello A., Ferrari A., Gaudiosi D., Sabo A., Pellegrini V., Beltram F., Giacca M., and Carloni P. Insights on HIV-1 Tat:P/CAF bromodomain molecular recognition from in vivo experiments and molecular dynamics simulations. Proteins 62 (2006) 1062-1073
59. Pantano S., Berrera M., Anselmi C., and Carloni P. Tetrameric voltage-gated ion channels investigated by molecular dynamics and bioinformatics. In: Broglia A., Serrano L., and Tiana G. (Eds). Protein folding and drug design: Varenna on Lake Como, Villa Monastero, 4-14 July 2006 (2007), IOS Press, Washington, DC Società italiana di fisica, Bologna, Italy
60. Noguti T., and Go N. Collective variable description of small-amplitude conformational fluctuations in a globular protein. Nature 296 (1982) 776-778
61. Car R., and Parrinello M. Unified approach for molecular dynamics and density-functional theory. Phys. Rev. Lett. 55 (1985) 2471-2474
62. Essmann U., Perera L., Berkovitz M.L., Darden T., Lee H., and Pedersen L.G. A smooth particle mesh Ewald method. J. Chem. Phys. 103 (1995) 8577-8593
63. Nosé S. A unified formulation of the constant temperature molecular dynamics method. J. Chem. Phys. 81 (1984) 511-519
64. Parrinello M., and Rahman A.J. Polymorphic transitions in single crystals: A new molecular dynamics method. J. Appl. Phys. 52 (1981) 7182-7190
65. Hess B., Bekker H., Berendsen H.J.C., and Fraaije J.G.E.M. LINCS: a linear constraint solver for molecular simulations. J. Comp. Chem. 18 (1997) 1463-1472
66. Becke A.D. Density-functional exchange-energy approximation with correct asymptotic behavior. Phys. Rev. A 38 (1988) 3098-3100
67. Lee C., Yang W., and Parr R.G. Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density. Phys. Rev. B Condens. Mat. 37 (1988) 785-789
68. Troullier N., and Martins J.L. Efficient pseudopotentials for plane-wave calculations. Phys. Rev. B Condens. Mat. 43 (1991) 1993-2006
69. Van Der Spoel D., Lindahl E., Hess B., Groenhof G., Mark A.E., and Berendsen H.J. GROMACS: fast, flexible, and free. J. Comp. Chem. 26 (2005) 1701-1718
70. Holm L., and Sander C. Mapping the protein universe. Science 273 (1996) 595-603
71. Amadei A., Linssen A.B., and Berendsen H.J. Essential dynamics of proteins. Proteins 17 (1993) 412-425
72. Garcia A.E. Large-amplitude nonlinear motions in proteins. Phys. Rev. Lett. 68 (1992) 2696-2699